1. Steering committee member of “Phase 3, Randomized, Double-Arm, Open-Label, controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must be Systemic Therapy” and “Phase 2 Single-arm Study of ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck, With or Without Metastases, Not Amenable to Curative Local Treatment” 2. International Advisory Board Member for head and neck cancer (MSD and Rakuten Medical) 3. Cooperated with more than 40 international organizations for head and cancer treatment (Lancet Oncol 2020; 21(7):e350-e359. doi: 10.1016/S1470-2045(20)30334-X.)